NCT04602715View on ClinicalTrials.gov

The Safety, Efficacy, and Tolerability of Microbial Ecosystem Therapeutic-2 in People With Major Depression

PHASE2UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2021

Conditions
Major Depressive DisorderAnxiety
Interventions
DRUG

MET-2

Subjects will take capsules containing MET-2 daily during the trial. There will be a loading dose at the start of dosing, and a daily dose. There will be a booster dose given at week 2 and a second booster dose taken at week 4 for those subjects who have not improved by that time.

DRUG

Placebo

Placebo Control

Trial Locations (2)

K7L4X3

RECRUITING

Providence Care Hospital, Kingston

M6J1H4

RECRUITING

CAMH, Toronto

Sponsors

Lead Sponsor

NuBiyota
All Listed Sponsors
lead

NuBiyota

OTHER

NCT04602715 - The Safety, Efficacy, and Tolerability of Microbial Ecosystem Therapeutic-2 in People With Major Depression | Biotech Hunter | Biotech Hunter